On Friday, Lexaria Bioscience Corp (NASDAQ: LEXX) opened higher 8.94% from the last session, before settling in for the closing price of $1.23. Price fluctuations for LEXX have ranged from $0.77 to $2.43 over the past 52 weeks.
Annual sales at Healthcare sector company grew by 14.15% over the past five years. Company’s average yearly earnings per share was noted 47.69% at the time writing. With a float of $20.79 million, this company’s outstanding shares have now reached $22.23 million.
Lexaria Bioscience Corp (LEXX) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Lexaria Bioscience Corp is 6.45%, while institutional ownership is 7.73%. The most recent insider transaction that took place on Jul 29 ’25, was worth 14,375. In this transaction Director of this company bought 15,600 shares at a rate of $0.92, taking the stock ownership to the 270,012 shares. Before that another transaction happened on Jul 30 ’25, when Company’s Director bought 11,900 for $0.91, making the entire transaction worth $10,866. This insider now owns 281,912 shares in total.
Lexaria Bioscience Corp (LEXX) Latest Financial update
If we go through the results of last quarter, which was made public on 11/30/2024, the company posted -0.16 earnings per share (EPS) for the quarter, coming under the agreed prediction (set at -0.12) by -0.04. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.15 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 47.69% per share during the next fiscal year.
Lexaria Bioscience Corp (NASDAQ: LEXX) Trading Performance Indicators
Check out the current performance indicators for Lexaria Bioscience Corp (LEXX). In the past quarter, the stock posted a quick ratio of 2.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 41.94.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.66 and is forecasted to reach -0.33 in one year’s time.
Technical Analysis of Lexaria Bioscience Corp (LEXX)
Lexaria Bioscience Corp (NASDAQ: LEXX) saw its 5-day average volume 0.26 million, a negative change from its year-to-date volume of 0.26 million. As of the previous 9 days, the stock’s Stochastic %D was 83.09%.
During the past 100 days, Lexaria Bioscience Corp’s (LEXX) raw stochastic average was set at 72.91%, which indicates a significant decrease from 77.27% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0904 in the past 14 days, which was higher than the 0.0900 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0184, while its 200-day Moving Average is $1.0957. Nevertheless, the first resistance level for the watch stands at $1.4300 in the near term. At $1.5200, the stock is likely to face the second major resistance level. The third major resistance level sits at $1.6000. If the price goes on to break the first support level at $1.2600, it is likely to go to the next support level at $1.1800. The third support level lies at $1.0900 if the price breaches the second support level.
Lexaria Bioscience Corp (NASDAQ: LEXX) Key Stats
There are currently 22,226K shares outstanding in the company with a market cap of 29.78 million. Presently, the company’s annual sales total 710 K according to its annual income of -11,900 K. Last quarter, the company’s sales amounted to 170 K and its income totaled -2,700 K.
